Potential of outpatient steroid therapy in elderly patients with early COVID-19.

Autor:	Luzzati, Roberto, De Luca, Marina, Sanson, Gianfranco, Borelli, Massimo, Biolo, Gianni, Giacomazzi, Donatella, Zerbato, Verena, Di Bella, Stefano
Předmět:	VIRAL pneumonia DRUG efficacy COVID-19 ADRENOCORTICAL hormones OUTPATIENT medical care SCIENTIFIC observation RESPIRATORY insufficiency HOME care services AGE distribution RETROSPECTIVE studies ANTIVIRAL agents HOSPITAL mortality SEVERITY of illness index COMPARATIVE studies DESCRIPTIVE statistics PREDNISONE EVALUATION MIDDLE age OLD age
Zdroj:	Aging Clinical & Experimental Research; Oct2022, Vol. 34 Issue 10, p2585-2590, 6p
Abstrakt:	Corticosteroids lower mortality in hospitalized patients with COVID-19 pneumonia requiring oxygen support. In this observational retrospective study (September 2020–June 2021), we explored the association between receiving home corticosteroids without oxygen supply and 30-day mortality in hospitalized patients with COVID-19 pneumonia. Among a total of 794 COVID-19 pneumonia patients, 763 were included into the study (males 68%; mean age 65 ±12 years), of whom 197 (26%) received home corticosteroids (mean daily prednisone equivalent-dose 40 mg ± 12 mg; range 10–50 mg; median 50 mg; IQR 25–50 mg; for 4 days). The overall 30-day mortality of the study population was 12%. The risk of death—adjusted for age, comorbidities, administration of remdesivir and respiratory failure severity—was lower (HR 0.405; p = 0.024) in patients receiving home corticosteroids. After stratifying the study population by age categories, home corticosteroids were associated with an adjusted decrease in mortality risk in patients > 77 years (HR 0.346; p = 0.040). Home corticosteroids may lower the 30-day mortality in elderly COVID-19 patients. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink